LifeStance Q2 2026 Earnings: Revenue Rises 26% as Profitability Expands

LifeStance Health Group (NASDAQ: LFST) reported Q2 2026 revenue of $435.4 million, up 26% year over year, while diluted EPS improved to $0.06 from a loss of $0.01 for the quarter ended June 30, 2026. Net income turned positive, adjusted EBITDA margin expanded to 15.2%, and quarterly free cash flow reached $87.9 million. The company also raised its full-year revenue, Center Margin, and adjusted EBITDA outlook.

Core Earnings Data

Revenue growth was primarily driven by higher visit volume from clinician expansion, improved clinician productivity, and higher total revenue per visit. These factors also helped revenue grow faster than major operating costs, producing positive GAAP operating income and net income.

The quarter showed improvement across both GAAP and company-defined non-GAAP measures. Dollar amounts below are in millions except per-share data.

Center Margin, adjusted EBITDA, and free cash flow are non-GAAP measures. LifeStance defines free cash flow as operating cash flow less purchases of property and equipment.

Clinician Growth and Productivity Drove Visit Volume

LifeStance ended the quarter with 8,542 clinicians, an increase of 11% from the prior-year period. The company added 193 clinicians on a net basis sequentially during Q2.

Visit volume increased 19% to 2.6 million, outpacing clinician growth. Management attributed the increase to both a larger clinician base and improved productivity. Revenue rose faster than visit volume, reflecting the additional benefit of higher total revenue per visit.

LifeStance did not provide revenue by geography, specialty, or care channel, so the disclosed operating metrics offer the clearest view of the quarter’s underlying growth.

Profitability, Cash Flow, and Balance Sheet

Revenue growth translated into operating leverage

Center Margin expanded to 35.2% of revenue from 31.4%, indicating that center costs consumed a smaller share of revenue. LifeStance specifically attributed the improvement to higher revenue per visit and lower center costs as a percentage of revenue.

General and administrative expenses increased by about 11% to $108.1 million, compared with revenue growth of 26%. That gap created additional operating leverage, helping GAAP operating margin improve to 7.0% from negative 0.9% and adjusted EBITDA margin rise to 15.2% from 9.8%.

Adjusted EBITDA remained materially above GAAP net income. Its Q2 reconciliation included add-backs of $19.7 million in stock-based compensation, $14.2 million in depreciation and amortization, $3.8 million in income taxes, $2.6 million in net interest expense, and several smaller items.

Cash generation offset substantial investing and financing outflows

Operating cash flow totaled $99.9 million in Q2, producing $87.9 million of free cash flow. For the first six months of 2026, operating cash flow reached $133.0 million, more than double the $61.3 million generated in the prior-year period.

LifeStance ended June with $225.9 million in cash and cash equivalents, down $22.7 million from December 2025. The decline occurred despite stronger operating cash flow because the company used $31.8 million for investing activities and $123.9 million for financing activities during the first half. Financing outflows included $97.6 million of common-stock repurchases, while investing included $22.8 million of property and equipment purchases and $9.0 million for acquisitions.

Long-term debt, net, declined to $259.0 million from $265.9 million at year-end. The board also authorized a new repurchase program of up to $100 million, replacing the prior $100 million authorization approved on February 24, 2026.

Earnings Guidance

LifeStance raised its full-year expectations for revenue, Center Margin, and adjusted EBITDA, while also providing Q3 ranges. The source did not include the previous full-year ranges, so the size of each increase cannot be quantified.

Center Margin and adjusted EBITDA guidance are non-GAAP. LifeStance did not provide forward-looking reconciliations to the nearest GAAP measures because it said the necessary adjustments could not be estimated without unreasonable effort.

Management Commentary

CEO Dave Bourdon emphasized the combination of 26% revenue growth, positive net income, and a 15% adjusted EBITDA margin. Management plans to extend LifeStance’s geographic reach, expand specialty capabilities, and use clinical outcomes as a point of differentiation. Continued execution will depend on clinician recruitment, retention, and productivity as the company expands.

Recent Insider Transactions

The supplied insider dataset reported 2,872,636 shares purchased and 40,359,276 shares sold over the past six months, resulting in net sales of 37,486,640 shares across 30 transactions. The latest 10 reported transactions consisted of seven director stock awards at $0 and three director sales; the awards did not include share quantities in the supplied data.

These disclosures establish the transaction history but do not, by themselves, indicate insiders’ views on LifeStance’s outlook.

Risks Investors Need to Watch

• Clinician recruitment and retention: Revenue growth relied on an 11% larger clinician base and higher productivity. Slower hiring, clinician departures, or weaker productivity could pressure visit volume.
• Reimbursement and revenue per visit: Higher total revenue per visit supported both growth and margin expansion. Lower reimbursement from third-party payors could affect revenue and profitability simultaneously.
• Operating leverage may not persist: Q2 margins benefited because revenue grew faster than center costs and G&A expenses. Expansion into new geographies and specialties could weaken that relationship if expenses rise faster than revenue.
• Cash commitments and capital allocation: LifeStance used $97.6 million for repurchases in the first half and authorized another program of up to $100 million while carrying $259.0 million of long-term debt, net. Further repurchases could reduce liquidity available for expansion or debt reduction.

Conclusion

LifeStance’s Q2 2026 results showed that clinician growth, higher productivity, increased visit volume, and improved revenue per visit translated into positive GAAP earnings, wider margins, and substantial free cash flow. The raised outlook indicates that management expects the operating momentum to continue, while the main issues to monitor are clinician expansion, reimbursement, cost leverage, and cash deployment under the new repurchase authorization.